Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma

Cancer Immunology, Immunotherapy, 05/14/2012

Survivin–specific T–cell reactivities strongly correlate with tumor response and patient survival, indicating that vaccination with survivin–derived peptides is a promising treatment strategy in melanoma.

Print Article Summary Cat 2 CME Report